Friends welcomes Jeffrey Sturchio as new Chair of the Board and thanks Jonathan Klein for seven years as Chair

WASHINGTON, D.C. – Friends of the Global Fight Against AIDS, Tuberculosis and Malaria (Friends) is pleased to announce the appointment of Board Member Dr. Jeffrey L. Sturchio as the new Chair of the Board of Directors. Dr. Sturchio serves as the CEO at Rabin Martin, a global health strategy consulting firm. Prior to this role, he led the Global Health Council as President and CEO.

“Friends has benefitted greatly from Jeff’s expertise for many years and we are thrilled to see him take on the leadership role with the organization,” said Chris Collins, President of Friends. “Jeff brings a unique combination of private sector and NGO experience and is a powerful ally in the fight against AIDS, TB and malaria. I also want to thank Jonathan Klein, outgoing board Chair, for his incredible service to Friends as board chair for the last seven years. He’s been a fantastic leader and partner.”

Klein also expressed his enthusiasm for Sturchio’s appointment, saying, “Jeff’s diverse skillset and understanding of the global health sector will be a critical asset to the Friends board moving forward. I’m confident that Friends will be in good hands under his leadership.” Klein will become an emeritus member of the board. Linda Woolley will remain board Treasurer and Nicole Sexton will become board Secretary.

Dr. Sturchio launched his career in global health after receiving a Bachelor of Arts in history from Princeton University and a PhD in the history and sociology of science from the University of Pennsylvania. He served as vice president of corporate responsibility at Merck & Co. Inc., president of The Merck Company Foundation and chairman of the U.S. Corporate Council on Africa (CCA). While at Merck & Co., Inc., he led the company’s global HIV/AIDS policy and was centrally involved in the UN/Industry Accelerating Access Initiative, established in 2000 to help improve HIV/AIDS care and treatment in the developing world.

“I am honored to accept the role as Chair of the Board at such a pivotal time for Friends and the Global Fund,” said Dr. Sturchio. “Now more than ever, we need all actors to come together to increase investment in the Global Fund and help put a stop to these epidemics. I look forward to continue working together with fellow Board members and the Friends team to secure an increased U.S. commitment to the Global Fund as part of the upcoming 6th Replenishment.”

Dr. Sturchio also served as a member of the private sector delegation to the Board of the Global Fund to Fight AIDS, TB and Malaria from 2002-2008. He is currently chairman of the BroadReach Institute for Training and Education and the Corporate Council on Africa.

Dr. Sturchio’s many publications include the recent Road to Universal Health Coverage: Innovation, Equity and the New Health Economy (edited with I. Kickbusch and L. Galambos, Johns Hopkins University Press, 2019).

###

ABOUT FRIENDS OF THE GLOBAL FIGHT AGAINST AIDS, TUBERCULOSIS AND MALARIA: Friends of the Global Fight Against AIDS, Tuberculosis and Malaria advocates for U.S. support of the Global Fund, and the goal to end the epidemics of AIDS, tuberculosis and malaria. For more information about Friends of the Global Fight, visit www.theglobalfight.org.

ABOUT THE GLOBAL FUND: The Global Fund is a 21st-century partnership organization designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. Founded in 2002, the Global Fund is a partnership between governments, civil society, the private sector and people affected by the diseases. The Global Fund raises and invests nearly $4 billion a year to support programs run by local experts in countries and communities most in need. Working together, we have saved 27 million lives and provided prevention, treatment and care services to hundreds of millions of people, helping to revitalize entire communities, strengthen local health systems and improve economies. Learn more at https://www.theglobalfund.org/en/overview.

MEDIA CONTACT:
Sarah Hollis, [email protected]
202 912 3822